Analysis of Percutaneous Ablations for Cancer Treatment

Cancer Clinical Trial

Official title:

Prospective Analysis of Percutaneous Ablations for Cancer Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01563679
• Other study ID #: IRB00054905
• Secondary ID: RAD2160-11
• Status: Completed
• Phase: N/A
• First received: March 12, 2012
• Last updated: May 23, 2014
• Start date: February 2012
• Est. completion date: January 2014

Study information

• Verified date: May 2014
• Source: Emory University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

This is a study involving patients with cancer who are referred by their treating physician for percutaneous locoregional therapies.

Patient's clinical and radiology findings, pathology findings, survival, treatment responses, and complications after their locoregional therapy will be studied.

Description:

The efficacy of the percutaneous and transarterial treatments for solid tumors will be studied. Prospective study on patients who receive percutaneous locoregional therapies, including radiofrequency ablation (RFA), cryoablation, microwave ablation, IRE and chemical ablation for treatment of cancer will be performed.

Preoperative clinic chart, procedure note, postoperative chart, pre- and post-operative CT, MRI or Ultrasound, angiographic findings, biopsy results and pathologic findings, will be reviewed. Patient survival, treatment responses, complications after the therapy will be collected from clinic visits and clinical encounters.

Patient overall performance status before and after procedures will be assessed using the Quality of Life questionnaire (SF-36™ Health Survey).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: January 2014
• Est. primary completion date: January 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18yrs of age

• Cancer diagnosis

• Candidate for Locoregional therapy

• Willingness to sign informed consent

Exclusion Criteria:

• Unable to sign informed consent

• Patients not eligible for locoregional therapies

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Cancer

Locations

Country	Name	City	State
United States	Emory University Hospital	Altanta	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
Emory University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effect of percutaneous and transarterial treatments for cancer in quality of life	Patients will complete the QOL questionnare during their follow up visits after procedure. 1 month, 3 months, 6 months and 1 year.	1 year	No
Secondary	response rate to percutaneous and transarterial treatment for cancer	Patients will be followed up 1, 3, 6 and 1year intervals after procedure.	1 month, 3 months, 6 months, 1 year.	No